Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.51 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.51 |
| ▸ | TTR | P02766 | 3/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.51 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.51 |
| ▸ | ALB | P02768 | 1/20 | 0.48 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.48 |
| ▸ | TOP2A | P11388 | 2/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | BCR | P11274 | 2/20 | 0.46 |
| ▸ | NQO2 | P16083 | 2/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4098539 | 1.00 | PTGS2 (0.51) | PTGS2CYP1A1TTRALOX5CYP1B1 | |
| SCHEMBL4091528 | 1.00 | PTGS2 (0.51) | PTGS2CYP1A1TTRALOX5CYP1B1 | |
| SCHEMBL1042432 | 1.00 | PTGS2 (0.51) | PTGS2CYP1A1TTRALOX5CYP1B1 | |
| SCHEMBL2516564 | 1.00 | PTGS2 (0.51) | PTGS2CYP1A1TTRALOX5CYP1B1 | |
| SCHEMBL4096915 | 1.00 | PTGS2 (0.51) | PTGS2CYP1A1TTRALOX5CYP1B1 | |
| SCHEMBL2514429 | 1.00 | PTGS2 (0.51) | PTGS2CYP1A1TTRALOX5CYP1B1 | |
| SCHEMBL4103357 | 1.00 | PTGS2 (0.51) | PTGS2CYP1A1TTRALOX5CYP1B1 | |
| SCHEMBL1044464 | 1.00 | PTGS2 (0.51) | PTGS2CYP1A1TTRALOX5CYP1B1 | |
| SCHEMBL2514977 | 1.00 | PTGS2 (0.51) | PTGS2CYP1A1TTRALOX5CYP1B1 | |
| SCHEMBL2515023 | 0.96 | TTR (0.50) | PTGS2CYP1A1TTRALOX5CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110250251-A1 | Cosmetic Methods And Compositions For Repairing Human Skin | MAES DANIEL H | 2011-10-13 | — | — | US | claimed |
| EP-2445511-B1 | SKIN REPAIR COMPOSITIONS COMPRISING CIRCADIAN GENE ACTIVATORS AND A SYNERGISTIC COMBINATION OF SIRT1 GENE ACTIVATORS | ELC MAN LLC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-8703161-B2 | Skin repair compositions comprising circadian gene activators and a synergistic combination of Sirt1 gene activators | ELC MANAGEMENT, LLC (US) | 2014-04-22 | — | — | US | disclosed |
| WO-2014004339-A2 | METHOD FOR STIMULATING CELLULAR BETA DEFENSINS | ELC MANAGEMENT LLC (US) | 2014-01-03 | — | — | WO | disclosed |
| EP-2445511-A2 | SKIN REPAIR COMPOSITIONS COMPRISING CIRCADIAN GENE ACTIVATORS AND A SYNERGISTIC COMBINATION OF SIRT1 GENE ACTIVATORS | ELC Management LLC (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20110250251-A1 | Cosmetic Methods And Compositions For Repairing Human Skin | MAES DANIEL H | 2011-10-13 | — | — | US | disclosed |
| WO-2011005406-A2 | SKIN REPAIR COMPOSITIONS COMPRISING CIRCADIAN GENE ACTIVATORS AND A SYNERGISTIC COMBINATION OF SIRT1 GENE ACTIVATORS | ELC MANAGEMENT LLC (US) | 2011-01-13 | — | — | WO | disclosed |
| US-20100028317-A1 | Skin Repair Compositions Comprising Circadian Gene Activators And A Synergistic Combination Of Sirt1 Gene Activators | ELC MANAGEMENT LLC | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100028317-A1 | Skin Repair Compositions Comprising Circadian Gene Activators And A Synergistic Combination Of Sirt1 Gene Activators | CRY1, PER2, SIRT1 | PTGS2 4175/4885CYP1A1 1738/4885TTR 3953/4885 |
| US-20110250251-A1 | Cosmetic Methods And Compositions For Repairing Human Skin | CUTA, ERCC1, OGG1 | PTGS2 3235/4885CYP1A1 253/4885TTR 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.